Related Experiment Videos
Human endothelial gelatinases and angiogenesis
M Nguyen1, J Arkell, C J Jackson
1Sutton Arthritis Research Laboratory, Royal North Shore Hospital, New South Wales 2065, St. Leonards, Australia.
The International Journal of Biochemistry & Cell Biology
|July 27, 2001
Summary
Matrix metalloproteinases (MMPs), specifically gelatinase A and B, are crucial for new blood vessel formation. Recent findings reveal novel regulatory pathways for these enzymes in human endothelial cells, offering potential therapeutic targets for diseases like cancer.
Area of Science:
- Biochemistry
- Cell Biology
- Molecular Medicine
Background:
- Endothelial cell invasion is vital for angiogenesis, requiring extracellular matrix degradation.
- Matrix metalloproteinases (MMPs), particularly gelatinase A and B, are key enzymes in this process.
- Understanding MMP regulation in endothelial cells is crucial for targeting angiogenic diseases.
Purpose of the Study:
- To review recent findings on the regulation of gelatinase A and B in human endothelial cells.
- To highlight novel activators and regulatory mechanisms of gelatinase A.
- To explore the therapeutic potential of targeting these MMPs in angiogenic diseases.
Main Methods:
- Review of current literature on MMPs in angiogenesis.
- Analysis of gelatinase A and B secretion and activation pathways in endothelial cells.
- Identification of physiological activators and their mechanisms.
Main Results:
- Latent gelatinase B is secreted by endothelial cells and can accumulate as an active form in the cytosol.
- Latent gelatinase A is constitutively secreted and activated on the cell membrane via MT1-MMP.
- Thrombin and activated protein C activate gelatinase A independently of MT1-MMP.
Conclusions:
- Gelatinase A and B regulation in endothelial cells is complex, involving distinct secretion and activation mechanisms.
- Novel activators of gelatinase A present new therapeutic avenues.
- Targeting these MMP pathways could lead to treatments for cancer and arthritis.